Latest Content

Poor cardiovascular health, especially high BMI and poor sleep, is linked to a substantially higher risk of overactive bladder, new data show.

A VESALIUS-CV analysis found a 20% reduction in all-cause death with evolocumab in patients without prior MI or stroke, emerging after 1.5 years.

Review finds 91 new lung cancer screening and pulmonary nodule AI tools, but few get external validation or calibration, risking flawed LDCT decisions.

A newly validated scoring instrument extends alopecia areata assessment to the eyebrows, eyelashes, and beard.

Data show most older adults with newly diagnosed AML expect stable or improving physical function, while oncologists anticipate decline.

This extension to smaller drugmakers addresses a gap that has increasingly drawn attention from policy watchers.

Selinexor, an oral XPO1 inhibitor, delivers modest spleen volume reduction in ruxolitinib-refractory MF with minimal myelosuppression in ESSENTIAL trial news.

Updated systematic review finds GLP-1 therapies deliver substantial weight loss, with newer multiagonists and oral options expanding treatment choice.

A Chest study of 1576 patients finds a 20% emphysema threshold best predicts survival and lung function decline in fibrotic ILD.